Compare SRRK & APPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRRK | APPF |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 6.6B |
| IPO Year | 2018 | 2015 |
| Metric | SRRK | APPF |
|---|---|---|
| Price | $47.49 | $180.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | $56.17 | ★ $286.78 |
| AVG Volume (30 Days) | ★ 1.0M | 367.7K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.36 |
| Revenue | N/A | ★ $950,822,000.00 |
| Revenue This Year | N/A | $19.69 |
| Revenue Next Year | $534.24 | $16.70 |
| P/E Ratio | ★ N/A | $76.35 |
| Revenue Growth | N/A | ★ 19.72 |
| 52 Week Low | $27.07 | $142.56 |
| 52 Week High | $58.49 | $323.34 |
| Indicator | SRRK | APPF |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 55.37 |
| Support Level | $45.83 | $157.79 |
| Resistance Level | $48.23 | $187.38 |
| Average True Range (ATR) | 2.20 | 8.39 |
| MACD | -0.65 | 0.27 |
| Stochastic Oscillator | 5.15 | 64.28 |
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.